Climb Bio, Inc. (CLYM) · Oct 23, 2026 · Other events

Climb Bio clinical data bolster CLYM116’s 12-week dosing case

Above the bar — ≥90% APRIL suppression through 12 weeks; ~70% Gd-IgA1 reduction at 12 weeks

Climb Bio’s clinical data extend CLYM116’s APRIL suppression and biomarker results across two Phase 1 studies, but patient efficacy remains ahead.

The setup: Climb Bio is a clinical-stage immunology biotech advancing two antibody programs, with CLYM116 now in Phase 2 for IgA nephropathy and budoprutug in earlier-stage studies across additional immune diseases. The September 3, 2026 readout had already established the core story: roughly a 29-day half-life, more than 90% APRIL suppression, 60–75% IgA/Gd-IgA1 suppression through 12 weeks, and a potential every-12-week regimen.

This filing upgrades the evidence from one study to a broader package: CLYM116 now shows an estimated 33-day half-life across the 800 mg and 320 mg multiple-ascending-dose cohorts. 〔0〕 More importantly, the Australia and China Phase 1 studies produced consistent pharmacokinetics, while doses of at least 480 mg sustained 90% or greater free-APRIL suppression across the full 12-week interval. That makes the Q12W design look less dependent on a single dataset and more credible as the program’s development backbone.

The biomarker result is directionally supportive, but still not patient efficacy: At the selected 800 mg loading dose, Gd-IgA1 fell approximately 70% and IgA approximately 60% at week 12. 〔1〕 Those are useful pharmacodynamic signals for an anti-APRIL IgA-nephropathy drug, but the participants were healthy volunteers, so the decisive test remains whether the same exposure produces meaningful kidney-related outcomes in patients.

Safety remains clean enough to preserve momentum: Across 88 healthy volunteers, there were no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia; the five injection-site reactions were all Grade 1 and resolved without intervention. 〔2〕 This is confirmation rather than a major surprise, since the September dataset had already reported a favorable tolerability profile.

The next value-creating step is now patient validation: NAVIGATE-2 is enrolling and is intended to confirm the Q12W regimen, with initial data still expected in the first half of 2027. The planned 2027 Phase 3 start remains contingent on regulatory feedback, so today’s release strengthens the rationale for advancing the program but does not remove the central clinical-development risk.

Bottom line: This is a useful incremental upgrade, not a brand-new thesis: CLYM116’s long-interval dosing and pharmacodynamic profile now look more consistently supported across studies. The story still turns on whether those healthy-volunteer signals translate into patient benefit in NAVIGATE-2.

What to watch next

NAVIGATE-2 Phase 2 data, first half of 2027

Original filing on SEC EDGAR

More Climb Bio, Inc. news

• Climb Bio earnings beat as 2027 clinical milestones move into view
• Climb Bio Phase 2 data clear pMN bar, higher dose unproven
• Climb Bio's CLYM116 clears the PK/PD bar, but IgAN efficacy remains untested
• CLYM116 hits Phase 2 on schedule—but brings no patient data
• Quarterly loss beat estimates, but pipeline progress largely met expectations